585
Participants
Start Date
April 30, 2008
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
placebo
Patients receive placebo once daily
BIBW 2992
Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
1200.23.038 Boehringer Ingelheim Investigational Site, Kingman
1200.23.046 Boehringer Ingelheim Investigational Site, Fayetteville
1200.23.027 Boehringer Ingelheim Investigational Site, Anaheim
1200.23.028 Boehringer Ingelheim Investigational Site, Berkeley
1200.23.029 Boehringer Ingelheim Investigational Site, Modesto
1200.23.045 Boehringer Ingelheim Investigational Site, Montebello
1200.23.009 Boehringer Ingelheim Investigational Site, Orange
1200.23.026 Boehringer Ingelheim Investigational Site, Palm Springs
1200.23.024 Boehringer Ingelheim Investigational Site, North Miami Beach
1200.23.020 Boehringer Ingelheim Investigational Site, New York
1200.23.013 Boehringer Ingelheim Investigational Site, Valhalla
1200.23.056 Boehringer Ingelheim Investigational Site, Salt Lake City
1200.23.039 Boehringer Ingelheim Investigational Site, Renton
1200.23.050 Boehringer Ingelheim Investigational Site, Seattle
1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem
1200.23.32003 Boehringer Ingelheim Investigational Site, Ghent
1200.23.32001 Boehringer Ingelheim Investigational Site, Leuven
1200.23.32005 Boehringer Ingelheim Investigational Site, Liège
1200.23.32006 Boehringer Ingelheim Investigational Site, Namur
1200.23.1002 Boehringer Ingelheim Investigational Site, Edmonton
1200.23.1005 Boehringer Ingelheim Investigational Site, Vancouver
1200.23.1009 Boehringer Ingelheim Investigational Site, Toronto
1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal
1200.23.1004 Boehringer Ingelheim Investigational Site, Montreal
1200.23.86001 Boehringer Ingelheim Investigational Site, Beijing
1200.23.86002 Boehringer Ingelheim Investigational Site, Beijing
1200.23.86003 Boehringer Ingelheim Investigational Site, Beijing
1200.23.86009 Boehringer Ingelheim Investigational Site, Chengdu
1200.23.86007 Boehringer Ingelheim Investigational Site, Guangzhou
1200.23.86008 Boehringer Ingelheim Investigational Site, Hangzhou
1200.23.86004 Boehringer Ingelheim Investigational Site, Shanghai
1200.23.86005 Boehringer Ingelheim Investigational Site, Shanghai
1200.23.86006 Boehringer Ingelheim Investigational Site, Shanghai
1200.23.3303A Boehringer Ingelheim Investigational Site, Besançon
1200.23.3303C Boehringer Ingelheim Investigational Site, Besançon
1200.23.3305A Boehringer Ingelheim Investigational Site, Caen
1200.23.3304A Boehringer Ingelheim Investigational Site, La Tronche
1200.23.3304B Boehringer Ingelheim Investigational Site, La Tronche
1200.23.3307A Boehringer Ingelheim Investigational Site, Lyon
1200.23.3301A Boehringer Ingelheim Investigational Site, Paris
1200.23.3302A Boehringer Ingelheim Investigational Site, Paris
1200.23.3302B Boehringer Ingelheim Investigational Site, Paris
1200.23.3306A Boehringer Ingelheim Investigational Site, Toulouse
1200.23.3306C Boehringer Ingelheim Investigational Site, Toulouse
1200.23.49010 Zentralklinik Bad Berka GmbH, Bad Berka
1200.23.49002 Innere Klinik und Poliklinik (Tumorforschung), Essen
1200.23.49003 Asklepios Fachkliniken München-Gauting, Gauting
1200.23.49005 Krankenhaus Großhansdorf, Großhansdorf
1200.23.49008 Universitätsklinik Hamburg-Eppendorf, Hamburg
1200.23.49004 Johannes Gutenberg-Universität Mainz, Mainz
1200.23.49001 Universitätsklinikum Mannheim, Mannheim
1200.23.49006 HSK, Dr. Horst-Schmidt-Kliniken GmbH, Wiesbaden
1200.23.85202 Boehringer Ingelheim Investigational Site, Hong Kong
1200.23.39003 Boehringer Ingelheim Investigational Site, Genova
1200.23.39007 Boehringer Ingelheim Investigational Site, Orbassano (TO)
1200.23.39002 Boehringer Ingelheim Investigational Site, Perugia
1200.23.39004 Boehringer Ingelheim Investigational Site, Prato
1200.23.39008 Boehringer Ingelheim Investigational Site, Roma
1200.23.39001 Boehringer Ingelheim Investigational Site, Rozzano (MI)
1200.23.31002 Boehringer Ingelheim Investigational Site, Amsterdam
1200.23.31001 Boehringer Ingelheim Investigational Site, Groningen
1200.23.31003 Boehringer Ingelheim Investigational Site, Helmond
1200.23.65001 Boehringer Ingelheim Investigational Site, Singapore
1200.23.82005 Boehringer Ingelheim Investigational Site, Gyeonggi-do
1200.23.82006 Boehringer Ingelheim Investigational Site, Hwasun
1200.23.82001 Boehringer Ingelheim Investigational Site, Seoul
1200.23.82002 Boehringer Ingelheim Investigational Site, Seoul
1200.23.82003 Boehringer Ingelheim Investigational Site, Seoul
1200.23.82004 Boehringer Ingelheim Investigational Site, Seoul
1200.23.3405 Boehringer Ingelheim Investigational Site, Barcelona
1200.23.3404 Boehringer Ingelheim Investigational Site, Cruces
1200.23.3401 Boehringer Ingelheim Investigational Site, Madrid
1200.23.3403 Boehringer Ingelheim Investigational Site, Madrid
1200.23.3406 Boehringer Ingelheim Investigational Site, Madrid
1200.23.3402 Boehringer Ingelheim Investigational Site, Valencia
1200.23.88604 Taichung Veterans General Hospital, Taichung
1200.23.88605 China Medical University Hospital, Taichung
1200.23.88606 National Cheng Kung University Hospital, Tainan City
1200.23.88601 National Taiwan University Hospital, Taipei
1200.23.88602 Veterans General Hospital, Taipei
1200.23.88607 Tri-Service General Hospital, Taipei
1200.23.88603 Chang Gung Memorial Hosp-Linkou, Taoyuan District
1200.23.66001 Boehringer Ingelheim Investigational Site, Chiang Mai
1200.23.66003 Boehringer Ingelheim Investigational Site, Pathumwan, Bangkok
1200.23.66002 Boehringer Ingelheim Investigational Site, Songkhla
1200.23.4404 Boehringer Ingelheim Investigational Site, Dundee
1200.23.4403 Boehringer Ingelheim Investigational Site, Edinburgh
1200.23.4401 Boehringer Ingelheim Investigational Site, Glasgow
1200.23.4405 Boehringer Ingelheim Investigational Site, London
1200.23.4406 Boehringer Ingelheim Investigational Site, Sutton
Lead Sponsor
Boehringer Ingelheim
INDUSTRY